November 25, 2014
Read the news in Dermwire
The FDA announced the approval of Onexton Gel (clindamycin phosphate and benzoyl peroxide) 1.2%/3.75% for the treatment of acne.
This topical medication is approved for once-daily in the treatment of comedonal and inflammatory acne in patients 12 years and older.
“Acne is a pervasive disease that, if left unchecked, can have significant impact for patients” said Joshua Zeichner, MD, Director of Cosmetic and Clinical Research, Department of Dermatology, Mount Sinai Hospital. “We encourage people with acne to visit a dermatologist or other healthcare professional for treatment. Onexton Gel is an effective topical medication, appropriate for patients with a wide range of acne and has a favorable tolerability profile.”
Onexton is Valeant Pharmaceuticals International, Inc.’s latest medication to receive FDA approval. Valeant recently launched Jublia (efinaconazole) 10% for the treatment of superficial fungal infections, Retin-A Micro (tretinoin gel) microsphere 0.08% for the treatment of acne, and Luzu (luliconazole) for the treatment of athlete’s foot.